Clinical Trials Browser

Active not recruiting × Interventional × sapanisertib × Clear all

NCT03047213 2026-03-18

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2 Active not recruiting

17 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04250545 2025-11-25

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT06390865 2025-11-04

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Phase 2 Active not recruiting

LymphoidPlasma cell

Lymphoma, Multiple Myeloma